Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases

Abstract

The brain is a common metastatic site in lung cancer. Approximately one-third of patients will develop brain metastases during the course of their disease. Median overall survival has been reported between 3 and 14.8 months in patients with brain metastases compared to other metastatic sites. In addition, the lifetime incidence of brain metastases is increasing due to prolonged survival seen in non-small cell lung cancer (NSCLC) patients due to new systemic therapies and improved neuro-imaging techniques. Several targeted therapies—such as tyrosine kinase inhibitors targeting epidermal growth factor receptors and anaplastic lymphoma kinase—are active in NSCLC and have data to suggested possible effectiveness against brain metastases in these patients.

Keywords

Lung cancer EGFR ALK brain metastases

Get full access to this article

View all access options for this article.

References

Siegel

Miller

Jemal

. Cancer statistics. CA Cancer J Clin 2018; 68: 7–30.

Howlader N, Noone AM, Krapcho M, et al. (eds) SEER cancer statistics review, 1975–2014, Bethesda, MD: National Cancer Institute, https://seer.cancer.gov/csr/1975_2014/ (accessed 17 August 2018).

Fraumeni

Jr . Respiratory carcinogenesis: an epidemiologic appraisal. J Natl Cancer Inst 1975; 55: 1039–1046.

Finkelstein

Ettinger

Ruckdeschel

. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 702–709.

Remon

Besse

. Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment. Front Oncol 2018; 8: 88–88.

Sperduto

Kased

Roberge

et al.

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30: 419–425.

Sperduto

Yang

Beal

et al.

Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung-molGPA). JAMA Oncol 2017; 3: 827–831.

Howington

Blum

Chang

et al.

Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e278S–e313S.

Pallis

Gridelli

Wedding

et al.

Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Ann Oncol 2014; 25: 1270–1283.

10.

Rosenzweig

Chang

Chetty

et al.

ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. J Am Coll Radiol 2013; 10: 654–664.

11.

Douillard

Rosell

De Lena

et al.

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008; 72: 695–701.

12.

Schiller

Harrington

Belani

et al.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–87.

13.

Rong

Feng

. Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J Med Chem 2013; 56: 2–12.

14.

Brown

Jaeckle

Ballman

et al.

Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016; 316: 401–419.

15.

Brown

Ballman

Cerhan

et al.

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 1049–1060.

16.

Rangachari

Yamaguchi

VanderLaan

et al.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015; 88: 108–111.

17.

Zhu

Guo

et al.

Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. Oncotarget 2016; 7: 81906–81917.

18.

Gilotrif (afatinib) (prescribing information). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2018.

19.

Tarceva (erlotinib) (prescribing information). South San Francisco, CA: Genetech USA Inc., 2016.

20.

Iressa (gefitinib) (prescribing information). Wilmington, DE: AstraZeneca Pharmaceuticals, 2015.

21.

Tagrisso (osimertinib) (prescribing information). Wilmington, DE: AstraZeneca Pharmaceuticals, 2017.

22.

Soria

Ohe

Vansteenkiste

et al.

Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113–125.

23.

Schuler

Hirsh

et al.

First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 2016; 11: 380–390.

24.

Katayama

Shimizu

Suda

et al.

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4: 1415–1419.

25.

Zhou

Cheng

et al.

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013; 24: 993–999.

26.

Lee

Lewanski

Counsell

et al.

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst 2014; 106.

27.

Zhuang

Yuan

Wang

et al.

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther 2013; 7: 1179–1186.

28.

Welsh

Komaki

Amini

et al.

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013; 31: 895–902.

29.

Sperduto

Wang

Robins

et al.

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013; 85: 1312–1318.

30.

Iuchi

Shingyoji

Sakaida

et al.

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013; 82: 282–287.

31.

Ceresoli

Cappuzzo

Gregorc

et al.

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042–1047.

32.

Wang

et al.

Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007; 57: 359–364.

33.

Deng

et al.

Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009; 65: 198–203.

34.

Pesce

Klingbiel

Ribi

et al.

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2012; 48: 377–384.

35.

Goss

Tsai

Shepherd

et al.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol 2018; 29: 687–693.

36.

Mok

Y-L

Ahn

M-J

et al.

Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.

37.

Liu

Hsu

et al.

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. Expert Rev Anticancer Ther 2018; 18: 81–89.

38.

Johung

Yeh

Desai

et al.

Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 2016; 34: 123–129.

39.

Alecensa (alectinib) (prescribing information). South San Francisco, CA: Genentech USA, Inc., 2017.

40.

Alunbrig (brigatinib) (prescribing information). Cambridge, MA: Ariad Pharmaceuticals, Inc., 2017.

41.

Zykadia (ceritinib) (prescribing information). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2017.

42.

Xalkori (crizotinib) (prescribing information). New York, NY: Pfizer Labs, 2018.

43.

Costa

Shaw

et al.

Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 2015; 33: 1881–1888.

44.

Solomon

Mok

Kim

et al.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167–2177.

45.

Solomon

Cappuzzo

Felip

et al.

Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014. J Clin Oncol 2016; 34: 2858–2865.

46.

Crinò

Ahn

De Marinis

et al.

Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol 2016; 34: 2866–2873.

47.

Felip

Orlov

Park

et al.

Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol 2016; 27: 1208O–1208O.

48.

Soria

J-C

Tan

DSW

Chiari

et al.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017; 389: 917–929.

49.

Shaw

Kim

Crinò

et al.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18: 874–886.

50.

Peters

Camidge

Shaw

et al.

Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017; 377: 829–838.

51.

Gadgeel

Peters

Mok

TSK

et al.

1298O_PRAlectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Ann Oncol 2017; 28(suppl_5).

52.

Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017; 390: 29–39.

53.

Gadgeel

Shaw

Govindan

et al.

Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J Clin Oncol 2016; 34: 4079–4085.

54.

Novello

Mazieres

I-J

et al.

1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol 2017; 28.

55.

de Castro

Novello

Mazieres

et al.

1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC. Ann Oncol 2017; 28(suppl_5).

56.

Kim

Tiseo

Ahn

et al.

Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 2017; 35: 2490–2498.

57.

Ahn

Camidge

Tiseo

et al.

OA 05.05 brigatinib in crizotinib-refractory ALK+ NSCLC: updated efficacy and safety results from ALTA, a randomized phase 2 trial. J Thorac Oncol 2017; 12: S1755–S1756.

58.

Shaw

Kim

Mehra

et al.

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189–1197.

59.

Kodama

Tsukaguchi

Yoshida

et al.

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014; 351: 215–221.

60.

Ahn

De Petris

et al.

Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34: 661–668.

61.

Peters

Mok

et al.

Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol 2018; 36: abstract 9043–abstract 9043.